IFIT2 and non-small cell lung carcinoma: We performed drug sensitivity analyses using the CellMiner database and found that AP-26113 (Brigatinib), a tyrosine kinase receptor inhibitor and antitumor drug, significantly promoted IFIT1 and IFIT2 expression for the treatment of some forms of advanced non-small cell lung carcinoma [73].